Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis

Kidney International

Volumn 91, Issue 1, 2017, Pages 177-182

  Rheault, Michelle N ^a   Molony, Julia T ^b   Nevins, Thomas ^a   Herzog, Charles A ^b,c   Chavers, Blanche M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

anemia; cardiovascular disease; chronic kidney disease; pediatric nephrology

Indexed keywords

ALBUMIN; FERRITIN; HEMOGLOBIN; TRANSFERRIN; ANTIANEMIC AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHILD; CHILD HOSPITALIZATION; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEALTH CARE SURVEY; HEALTH CARE UTILIZATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; VALVULAR HEART DISEASE; ANEMIA; BLOOD; COMPARATIVE STUDY; COMPLICATION; HEART DISEASES; HOSPITALIZATION; KIDNEY FAILURE, CHRONIC; MORTALITY; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES;

ADOLESCENT; AGE FACTORS; ANEMIA; CHILD; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEMATINICS; HEMOGLOBINS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 85006365374     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.09.013     Document Type: Article

References (31)

1. 1 Gerson, A., Hwang, W., Fiorenza, J., et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44 (2004), 1017–1023.
2. 2 Roumelioti, M.E., Wentz, A., Schneider, M.F., et al. Sleep and fatigue symptoms in children and adolescents with CKD: a cross-sectional analysis from the chronic kidney disease in children (CKiD) study. Am J Kidney Dis 55 (2010), 269–280.
3. 3 Pickett, J.L., Theberge, D.C., Brown, W.S., et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33 (1999), 1122–1130.
4. 4 Martin, G.R., Ongkingo, J.R., Turner, M.E., et al. Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease. Pediatr Nephrol 7 (1993), 276–280.
5. 5 Drueke, T.B., Locatelli, F., Clyne, N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006), 2071–2084.
6. 6 Van Damme-Lombaerts, R., Broyer, M., Businger, J., et al. A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis. Pediatr Nephrol 8 (1994), 338–342.
7. 7 Besarab, A., Bolton, W.K., Browne, J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998), 584–590.
8. 8 Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
9. 9 Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
10. 10 KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 (2007), 471–530.
11. 11 Group KDIGOKAW. KDIGO Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2 (2012), 279–335.
12. 12 Mitsnefes, M.M., Laskin, B.L., Dahhou, M., et al. Mortality risk among children initially treated with dialysis for end-stage kidney disease, 1990-2010. JAMA 309 (2013), 1921–1929.
13. 13 Chavers, B.M., Molony, J.T., Solid, C.A., et al. One-year mortality rates in US children with end-stage renal disease. Am J Nephrol 41 (2015), 121–128.
14. 14 Chavers, B.M., Solid, C.A., Sinaiko, A., et al. Diagnosis of cardiac disease in pediatric end-stage renal disease. Nephrol Dial Transplant 26 (2011), 1640–1645.
15. 15 Mitsnefes, M.M., Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23 (2012), 578–585.
16. 16 Chavers, B.M., Li, S., Collins, A.J., et al. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 62 (2002), 648–653.
17. 17 Cheung, A.K., Sarnak, M.J., Yan, G., et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65 (2004), 2380–2389.
18. 18 Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis, 66(1 Suppl 1), 2015, Svii S1–S305.
19. 19 Investigators, E.T., Chertow, G.M., Block, G.A., et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 (2012), 2482–2494.
20. 20 Wheeler, D.C., London, G.M., Parfrey, P.S., et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc, 3, 2014, 001363.
21. 21 Amaral, S., Hwang, W., Fivush, B., et al. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 17 (2006), 2878–2885.
22. 22 Lestz, R.M., Fivush, B.A., Atkinson, M.A., Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 29 (2014), 2021–2028.
23. 23 Civilibal, M., Oflaz, H., Caliskan, S., et al. Left ventricular systolic and diastolic function and carotid intima-media thickness in pediatric dialysis patients. Int Urol Nephrol 41 (2009), 401–408.
24. 24 Chavarria, L.A., Aguilar-Kitsu, A., Rosas, P., et al. Intima media thickness in children undergoing dialysis. Pediatr Nephrol 27 (2012), 1557–1564.
25. 25 Srivaths, P., Krishnamurthy, R., Brunner, L., et al. Cardiac calcifications are more prevalent in children receiving hemodialysis than peritoneal dialysis. Clin Nephrol 81 (2014), 231–237.
26. 26 Dahlinghaus, E.K., Neu, A.M., Atkinson, M.A., et al. Hemoglobin level and risk of hospitalization and mortality in children on peritoneal dialysis. Pediatr Nephrol 29 (2014), 2387–2394.
27. 27 Borzych-Duzalka, D., Bilginer, Y., Ha, I.S., et al. Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24 (2013), 665–676.
28. 28 Ma, J.Z., Ebben, J., Xia, H., et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10 (1999), 610–619.
29. 29 Foley, R.N., Parfrey, P.S., Harnett, J.D., et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28 (1996), 53–61.
30. 30 Xia, H., Ebben, J., Ma, J.Z., et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10 (1999), 1309–1316.
31. 31 Collister, D., Komenda, P., Hiebert, B., et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 164 (2016), 472–478.